Ted Kubicki, MD
Family Medicine · Virginia Beach, VANPI 1891760138
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $3,578 of the $4,474 with a category attached, or 80.0%. Every reported general payment came from a single manufacturer, Novo Nordisk.
Across 7 payments — averaging $639.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$4K
Across 83 payments — averaging $1858.35 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$150K
- AstraZeneca$5K
What the payments were for
- Consulting fees$3,57880%
- Travel & lodging$87720%
- Food & beverage$80%
- Education$120%
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 7 | $4,474 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Victoza$4,443
How this compares
$4,474 in reported general payments places this provider in the 85th percentile of 2,553 family medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 131 | $127,250 |
| TrulicityDulaglutide | 85 | $116,989 |
| OzempicSemaglutide | 62 | $86,666 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 40 | $47,546 |
| XareltoRivaroxaban | 41 | $39,528 |
| JardianceEmpagliflozin | 40 | $37,217 |
| FarxigaDapagliflozin Propanediol | 49 | $33,984 |
| JanuviaSitagliptin Phosphate | 14 | $18,698 |
| RybelsusSemaglutide | 11 | $14,296 |
| Spiriva RespimatTiotropium Bromide | 26 | $13,394 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 30 | $12,638 |
| LinzessLinaclotide | 13 | $12,252 |
| Tresiba Flextouch U-100Insulin Degludec | 18 | $7,499 |
| Atorvastatin Calcium | 691 | $7,026 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 46 | $6,618 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $4,474 | $100,96273 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,553 family medicine providers in Virginia.
Other family medicine in Virginia Beach
- Jim-David GaglioneVirginia Beach$24K
- Michael CharlesVirginia Beach$18K
- Glenn McDermottVirginia Beach$18K
- Nasser HambazVirginia Beach$14K
- Oluwaronke AwosikaFort Gregg Adams$397K
- Monique MatuskowitzNorfolk$110K
- Paul StairsRichmond$105K
- Edwin RobinsonRichmond$83K
- Benjamin PhilpottRocky Mount$64K
- John MolaiyArlington$64K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.